** Biotech firm Aligos Therapeutics'ALGS.O shares fall 17.3% to $10.70, hit three-month low
** Company posts quarterly net loss of $13.08 per share vs loss of $5.50 per share a year earlier
** Reports cash equivalents and investments in 2024 of $56.9 million vs $135.7 million in 2023, which will provide sufficient funding of planned operations into H2 2026
** Company says it is continuing to evaluate a variety of options to fund continued development of its liver disease drug, including potential out-licensing
** As of last close, ALGS has fallen 44.3% in the past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。